NPLC0393 from Gynostemma pentaphyllum ameliorates Alzheimer's disease‐like pathology in mice by targeting protein phosphatase magnesium‐dependent 1A phosphatase

Abstract

AbstractAlzheimer's disease (AD) is a neurodegenerative disease with clinical hallmarks of progressive cognitive impairment and memory loss. Gynostemma pentaphyllum ameliorates cognitive impairment, but the mechanisms remain obscure. Here, we determine the effect of triterpene saponin NPLC0393 from G. pentaphyllum on AD‐like pathology in 3×Tg‐AD mice and elucidate the underlying mechanisms. NPLC0393 was administered daily in vivo by intraperitoneal injection for 3 months and its amelioration on the cognitive impairment in 3×Tg‐AD mice was assessed by new object recognition (NOR), Y‐maze, Morris water maze (MWM), and elevated plus‐maze (EPM) tests. The mechanisms were investigated by RT‐PCR, western blot, and immunohistochemistry techniques, while verified by the 3×Tg‐AD mice with protein phosphatase magnesium‐dependent 1A (PPM1A) knockdown (KD) through brain‐specific injection of adeno‐associated virus (AAV)‐ePHP‐KD‐PPM1A. NPLC0393 ameliorated AD‐like pathology targeting PPM1A. It repressed microglial NLRP3 inflammasome activation by reducing NLRP3 transcription during priming and promoting PPM1A binding to NLRP3 to disrupt NLRP3 assembly with apoptosis‐associated speck‐like protein containing a CARD and pro‐caspase‐1. Moreover, NPLC0393 suppressed tauopathy by inhibiting tau hyperphosphorylation through PPM1A/NLRP3/tau axis and promoting microglial phagocytosis of tau oligomers through PPM1A/nuclear factor‐κB/CX3CR1 pathway. PPM1A mediates microglia/neurons crosstalk in AD pathology, whose activation by NPLC0393 represents a promising therapeutic strategy for AD.